Source - LSE Regulatory
RNS Number : 9779E
Tissue Regenix Group PLC
01 March 2024
 

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

 

Notice of full year results

Investor presentation

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, will announce its final results for the year ended 31 December 2023 on Tuesday 19 March 2024.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the final results via the Investor Meet Company platform at 11.00am on Tuesday 19 March 2024. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

 

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

 

 

For more information:

 

Tissue Regenix Group plc

www.tissueregenix.com

David Cocke, Chief Financial Officer

via Walbrook PR



Cavendish Capital Markets Limited (Nominated Adviser and Broker) 


Emily Watts/Geoff Nash/George Dollemore - Corporate Finance


Nigel Birks/Harriet Ward - ECM


 


Walbrook PR (Financial PR and IR)

Tel: +44 (0)20 7933 8780

Alice Woodings/Charlotte Edgar

TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORDZGZZGLRGDZM
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Tissue Regenix Group PLC (TRX)

-1.00p (-1.61%)
delayed 14:46PM